Cabaletta Q2 2026: R&D $44.4M, cash $225.1M; rese-cel milestones on track

Cabaletta Bio, Inc.

R&D expenses $44.4M vs $37.6M in Q2 2025; G&A $7.6M vs $8.3M.
Cash and investments $225.1M at June 30, 2026, up from $133.6M at Dec 31, 2025; funds ops into mid-2027.
Registrational RESET-Myositis data on track for mid-2027; BLA submission planned 2H27 with juvenile data for Priority Review Voucher.
SSc-associated ILD registrational cohort (~25 patients) to initiate 4Q26; PC-free approach incorporated in RESET-MG.
ElevateBio selected as second CDMO alongside Lonza; 10-year supply agreement with Cellares announced April 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.